GlassScriptPhysician profile
Shirley Williams
NPI 1346298304
$5,555.99
in general payments reported to CMS, 2019-2025
31 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $307 · 2021: $388 · 2022: $529 · 2023: $1,163 · 2024: $1,230 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,575 · Education: $3.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,574.87 |
| Education | $3.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $863.20 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $787.11 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $759.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $707.57 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $381.20 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.62 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $210.06 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $152.28 | 2021-2025 | Nexletol |
| Amgen INC. | $137.87 | 2019-2024 | Repatha |
| Boston Scientific Corporation | $127.11 | 2021-2025 | Watchman Flx, Watchman Access System |
| Astellas Pharma US INC | $121.25 | 2019-2022 | |
| Cashflow Solutions, LLC | $120.02 | 2022-2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Lexicon Pharmaceuticals, INC. | $109.54 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $99.02 | 2019-2024 | Farxiga |
| Philips North America LLC | $84.84 | 2020-2024 | (Ck4) Mcot |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $68.49 | 2019 | |
| Inspire Medical Systems, INC. | $61.68 | 2023 | Inspire |
| Novo Nordisk INC | $50.97 | 2025 | Ozempic |
| Bard Peripheral Vascular, INC. | $43.29 | 2023 | Venovo |
| Amarin Pharma, INC. | $40.54 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $38.87 | 2021-2022 | |
| Medtronic, INC. | $34.13 | 2025 | Azure Xt Dr Mri Surescan |
| Scpharmaceuticals INC. | $33.23 | 2023-2024 | |
| Bardy Diagnostics, INC. | $20.00 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.97 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $19.76 | 2024 | Arcalyst |
| Baxter Healthcare | $18.91 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Abbott Laboratories | $18.78 | 2023 | Assurity |
| Bayer Healthcare Pharmaceuticals INC. | $18.29 | 2025 | |
| Azurity Pharmaceuticals, INC. | $14.48 | 2023 | Edarbyclor |
| Arbor Pharmaceuticals, INC. | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirley Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.